Erzsébet Merényi, Professor of Statistics Research at Rice University, and co-founders at the University of Texas MD Anderson Cancer Center Pratip Bhattacharya, Professor of Cancer Systems Imaging, and Dr. Patrick Pilié, Assistant Professor Genitourinary Medical Oncology deadly forms of prostate cancer earlier and improve the choice of treatment.
Prostate cancer is the most commonly diagnosed cancer among men, but the effects of patients vary widely. Because the development of prostate cancer is powered by male hormones, especially testosterone, the most widely used therapies today target and prevent the effects of these hormones. Known as androgen signaling inhibitors, drugs are used to slow down or shrink cancer, but over time, some cancers adapt and develop resistance. For men with prostate -resistant to castration, treatment options remain limited and survival rates are poor.
Changes in cellular metabolism in cancer patients can serve as biomarkers, and the use of advanced imaging techniques to detect these changes is a promising way to monitor processes associated with sensitivity to cancer treatment and even the appearance of premeditations. However, the complex nature of data is a challenge for the traditional methods of statistics and mechanical analysis.
The survey supported by this CPRIT grant is based on three pillars:
● Revolutionary non -invasive imaging in the Bhattacharya laboratory produces in vivo time and spectral profiles of metabolism of tumors in unprecedented detail, which allows for sensitive distinction between different deviations and makes it possible to map the heterogeneity of the tumor.
● To form and formally model and model such situations, Merényi’s team will implement an advanced AI format inspired by brain networks that are particularly experienced in discovering from complex, high -dimensional data.
● Continuing clinical trials of systemic treatment with androgen signaling inhibitors in a different population of men with prostate cancer in the Pilié laboratory (along with Bhattacharya mouse model data) will provide unique rich human data on therapeutic efficacy. Clinical data will allow the interpretation of discovered variants in metabolic signatures and help identify clinically related biological markers or biological signals that indicate which patients bear the greatest risk of developing aggressive forms of the disease early in diagnosis.
The successful application of these three pillars will allow previous and more accurate interventions tailored to the profile of each patient’s disease.
A fascinating key aspect of the study is the way AI approaches and applies by the Merényi team earlier in astronomy and reminders of the Earth can now help patients with prostate cancer and other cancers in the near future. This highlights the benefits of intersecting fertilization in all scientific approaches to interdisciplinary cooperation.
“Using mechanical learning based on the nervous map, we can reveal hidden standards in high -dimensional data, including rare or thin patterns that may be the most important, to help clinicians to detect earlier and prostate cancer and prostate cancer. Merényi.
With the development of AI -based models that can handle the complexity of multiple cancer data, the project funded by CPRIT could provide a plan for AI use in other fields of oncology and personalized medicine.
CPRIT is leading the fight against cancer state, having awarded more than $ 3.7 billion in grants to Texas institutions and organizations through academic research research programs. CPRIT has played a crucial role in hiring top researchers in Texas, supporting innovative newly established businesses and providing millions of cancer prevention services throughout the State.
This latest grant highlights CPRIT’s commitment to invest in innovative research that has the potential to convert cancer diagnosis and treatment.
